VenoValve to be Featured During Presentation at the 47th Annual Charing Cross SymposiumIRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the VenoValve® will be featured during a presentation at the Annual Charing Cross Symposium being held April 23-25, 2025 in London, England.
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell SegmentModerated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual SymposiumIRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (
NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52nd Annual Symposium being held March 29-April 2, 2025 in Austin, TX.
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter MeetingTwo-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA ApprovalDefinitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)First wave of implants successfully completed with updated delivery system performing very well
BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public OfferingenVVeno Medical (
NASDAQ: NVNO), a late-clinical stage medical device company setting new standards of care for the treatment of venous diseases, recently announced the pricing of an underwritten public offering. Led by existing institutional investors, the offering involved the issuance and sale of 4,285,715 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per unit. enVVeno expected to receive aggregate gross proceeds from the offering of about $15.0 million. The offering was anticipated to close on or about September 30, 2024, subject to customary closing conditions.
